Shire

Tweet this page
<
2012
2013
2014
2015
2016
2017
2018
2019
>
No longer registered as of 27 Sep 2019 - Registration as it was on 17 Apr 2019
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

650,000€

Financial year: Jan 2018 - Dec 2018

Lobbyists (Full time equivalent)

2 Fte (6)

Lobbyists with EP accreditation

0

High-level Commission meetings

0

Lobbying Costs over the years

  • Info

    Shire   (Shire)

    EU Transparency Register

    60329985751-43 First registered on 28 Apr 2011

    Goals / Remit

    Shire is the leading global biotechnology company focused on serving people affected by rare diseases and highly specialized conditions. These diseases are often misunderstood, under-diagnosed, and potentially life-threatening.

    We are dedicated to expanding, building and sustaining leadership across our key therapeutic areas through our extensive portfolio of products, innovative pipeline and collaborative approach to working with diverse partners around the globe. We strive to earn and keep the trust of our patients, their families and physicians, and all others who support and advance their care.

    Main EU files targeted

    Note that on 8 January 2019 Takeda completed its acquisition of Shire. Takeda will provide a consolidated update on the combined company as part of its planned annual update, due by 13 September 2019.

    Shire follows all initiatives, policies, and legislation related to the biopharmaceutical sector and patient access to innovative medicines. These include:

    European Commission's annual work programme
    European Medicines Agency
    Healthcare policies
    Health Technology Assessment
    Innovative Medicines Initiative
    Intellectual Property
    Patient access to innovative medicines
    Patient safety
    Personalised medicines
    Pharmaceutical legislation
    Pharmaceutical sector policies
    Rare disease policies
    Research & Development

    Address

    Head Office
    Takeda
    Thurgauerstrasse 130 Glattpark-Opfikon
    Zurich 8152
    SWITZERLAND
    EU Office
    47, rue Montoyer
    Brussels 1000
    BELGIUM
  • People

    Total lobbyists declared

    6

    Employment timeLobbyists
    50%2
    25%4

    Lobbyists (Full time equivalent)

    2

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    0 accreditations were / are live (in bold) for the selected state of 15 Jun 2024

    Name Start date End Date
    Mr Richard CORLISS 12 Oct 2017 12 Oct 2018
    Toon DIGNEFFE 12 Oct 2017 12 Oct 2018
    Mr Richard CORLISS 30 Sep 2016 23 Sep 2017
    Ms Maria Joaquina RODRIGUEZ SANCHEZ 30 Sep 2016 22 Sep 2017
    Ms Astrid Jankowitsch 30 Sep 2016 27 Sep 2017
    Toon DIGNEFFE 30 Sep 2016 24 Sep 2017
    Mr Maciej Gajewski 11 Sep 2015 09 Sep 2016
    Mr Richard CORLISS 11 Sep 2015 09 Sep 2016
    Nicholas EDWARDS 16 May 2014 05 Jun 2015
    Emmanuel CHANTELOT 15 May 2014 05 Jun 2015
    Mr Maciej Gajewski 13 May 2014 05 Jun 2015

    Complementary Information

    None declared

    Person in charge of EU relations

    Mr Toon Digneffe (Head, EU Public Affairs)

    Person with legal responsibility

    Mr Giles Platford (President EUCAN Business Unit)

  • Categories

    Category

    II - In-house lobbyists and trade/business/professional associations

    Subcategory

    Companies & groups

  • Networking

    Affiliation

    European Association of Bioindustries (EuropaBio)
    European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
    European Federation of Pharmaceutical Industries and Associations (EFPIA)
    Plasma Protein Therapeutics Association (PPTA)

    American Chamber of Commerce to the European Union (AmCham EU)
    British Chamber of Commerce in Belgium
    European Policy Centre (EPC)
    Friends of Europe

    Member organisations

    None declared

  • Financial Data

    Closed financial year

    Jan 2018 - Dec 2018

    Lobbying costs for closed financial year

    650,000€

    Other financial info

    Activities covered: staff cost, trade associations membership fees, fees for public affairs consultancies and administrative expenses.
    This estimate is consistent with the guidance provided by EFPIA.

    Note that on 8 January 2019 Takeda completed its acquisition of Shire. Takeda will provide a consolidated update on the combined company as part of its planned annual update, due by 13 September 2019.

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    None

    Communication activities

    EU pharmaceutical legislation.
    European Commission review of intellectual property (IP) and incentives under EU legislation.
    The evaluation of EU legislation on medicines for children and rare diseases (EU Orphan Regulation, EU Paediatric Regulation).
    Follow-up actions related to the 2009 Council Recommendation on an action in the field of rare diseases.
    Debates and initiatives on pricing of and access to medicines.
    European cooperation on Health Technology Assessment.

    Other activities

    Shire engages in debates on issues relevant to the biopharmaceutical sector. Shire supports equal access to innovative medicines in Europe and research and innovation in the healthcare sector.

    Shire also interacts with the EU Institutions in relation to legislation which has impact on the industry, for example Shire participates in relevant public consultations.

  • Meetings

    Meetings

    None declared

Download this datacard